Veronica Rendo

Aug 14, 2024 | medrxiv.org | Veronica Rendo |Eudocia Q. Lee |Nicholas Khuu |Connor Bossi

N.Y.R.A is key opinion leader for Bruker Daltonics, and receives support from Thermo Finnegan and EMD Serono. The other authors declare no competing financial interests. NCT03107780This study was sponsored by the Adult Brain Tumor Consortium (ABTC) NIH/NCI UM1 CA137443, NIH grants U54-CA210180 (NYRA), P41-EB028741 (NYRA), U19CA264504, R01CA262462 (RB and KL), R0188228 (RB and KL), and Capital Award from the Massachusetts Life Sciences Center.

Dec 19, 2023 | biorxiv.org | Veronica Rendo |Michael Schubert |Kaimeng Huang |Nicholas Khuu

AbstractChromosomal gains are among the most frequent somatic genetic alterations occurring in cancer. While the effect of sustained oncogene expression has been characterized, the impact of copy-number gains affecting collaterally-amplified "bystander" genes on cellular fitness remains less understood. To investigate this, we built a comprehensive map of dosage compensation across human cancers by integrating expression and copy number profiles from over 8,000 TCGA tumors and CCLE cell lines.